Castle Biosciences will acquire Previse to enhance its gastrointestinal offerings, focusing on chronic acid reflux and esophageal cancer.
Quiver AI Summary
Castle Biosciences, Inc. has announced a definitive agreement to acquire Capsulomics, Inc., also known as Previse, which focuses on gastrointestinal health, specifically chronic acid reflux diseases and esophageal cancer. The deal will enhance Castle’s gastroenterology offerings, including their existing TissueCypher test, by incorporating Previse's innovative methylation technology developed at Johns Hopkins University. This merger aims to address unmet needs in GI care and provide more comprehensive testing options for patients. Both companies express optimism about the potential improvements in patient care stemming from this collaboration. The acquisition is expected to close in the coming weeks, pending customary conditions.
Potential Positives
- Acquisition of Previse is expected to complement Castle Biosciences’ existing gastroenterology franchise, enhancing their offerings in this critical medical area.
- Previse’s innovative methylation technology, developed at Johns Hopkins, adds significant potential to Castle’s product pipeline, addressing unmet needs in gastrointestinal health.
- The deal highlights Castle's commitment to growth and innovation within the GI community, likely strengthening their market position and appeal to customers.
Potential Negatives
- The terms of the acquisition agreement are undisclosed, which may raise concerns about the financial implications or risks associated with the purchase of Previse.
- The press release includes multiple forward-looking statements that carry inherent risks and uncertainties, suggesting that the anticipated benefits of the acquisition are not guaranteed and could differ materially from expectations.
- The reliance on a new technology developed at Johns Hopkins could pose risks, as subsequent study or trial results may contradict earlier findings or not support earlier results, leading to potential setbacks in product effectiveness or public perception.
FAQ
What is the purpose of Castle Biosciences acquiring Previse?
The acquisition aims to enhance Castle's gastrointestinal franchise and expand testing options for chronic acid reflux diseases.
What technology does Previse bring to Castle Biosciences?
Previse offers methylation technology developed at Johns Hopkins University, along with additional technologies for gastrointestinal health.
How does the acquisition benefit patients?
This collaboration aims to improve prevention and early detection of gastrointestinal diseases, particularly chronic acid reflux-related conditions.
When is the acquisition of Previse expected to close?
The transaction is anticipated to close in the coming weeks, subject to customary closing conditions.
What are the main products of Castle Biosciences?
Castle's portfolio includes tests for skin cancers, Barrett’s esophagus, mental health conditions, and more, addressing various clinical needs.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$CSTL Insider Trading Activity
$CSTL insiders have traded $CSTL stock on the open market 153 times in the past 6 months. Of those trades, 0 have been purchases and 153 have been sales.
Here’s a breakdown of recent trading of $CSTL stock by insiders over the last 6 months:
- DEREK J MAETZOLD (Pres. & Chief Exec. Officer) has made 0 purchases and 130 sales selling 101,587 shares for an estimated $2,639,325.
- DANIEL BRADBURY has made 0 purchases and 18 sales selling 23,601 shares for an estimated $694,555.
- FRANK STOKES (Chief Financial Officer) has made 0 purchases and 3 sales selling 14,969 shares for an estimated $422,045.
- TOBIN W JUVENAL (Chief Commercial Officer) has made 0 purchases and 2 sales selling 5,737 shares for an estimated $191,608.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$CSTL Hedge Fund Activity
We have seen 100 institutional investors add shares of $CSTL stock to their portfolio, and 100 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- UBS GROUP AG added 758,466 shares (+1401.1%) to their portfolio in Q4 2024, for an estimated $20,213,118
- WELLINGTON MANAGEMENT GROUP LLP added 722,120 shares (+inf%) to their portfolio in Q4 2024, for an estimated $19,244,498
- BELLEVUE GROUP AG removed 516,048 shares (-40.9%) from their portfolio in Q4 2024, for an estimated $13,752,679
- PORTOLAN CAPITAL MANAGEMENT, LLC removed 479,049 shares (-38.2%) from their portfolio in Q4 2024, for an estimated $12,766,655
- SOLEUS CAPITAL MANAGEMENT, L.P. removed 409,415 shares (-61.8%) from their portfolio in Q4 2024, for an estimated $10,910,909
- MILLENNIUM MANAGEMENT LLC added 408,272 shares (+290.5%) to their portfolio in Q4 2024, for an estimated $10,880,448
- JACOBS LEVY EQUITY MANAGEMENT, INC removed 361,739 shares (-72.9%) from their portfolio in Q4 2024, for an estimated $9,640,344
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$CSTL Analyst Ratings
Wall Street analysts have issued reports on $CSTL in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Guggenheim issued a "Buy" rating on 03/28/2025
To track analyst ratings and price targets for $CSTL, check out Quiver Quantitative's $CSTL forecast page.
Full Release
Expected to complement Castle’s current gastroenterology franchise
Adds methylation technology developed at the Johns Hopkins University School of Medicine and additional technologies in development
FRIENDSWOOD, Texas, May 05, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced it has signed a definitive agreement to acquire Capsulomics, Inc., d/b/a Previse. Previse is a gastrointestinal health company with a primary focus on chronic acid reflux related diseases, including esophageal cancer. The terms of the agreement are undisclosed.
“This proposed transaction underscores our commitment to the gastrointestinal (GI) community-providers and patients,” said Derek Maetzold, president and chief executive officer of Castle Biosciences. “Our growth initiatives include the continual assessment of complementary technologies. With Previse, we found an opportunity to expand our offerings within our GI vertical, beyond our spatialomics TissueCypher Barrett’s Esophagus test, allowing us to offer customers a more robust set of testing options. Previse’s methylation technology, as well as its pipeline technologies, provide us with the potential to address existing unmet needs, including potential upstream opportunities.”
“We are excited about joining Castle,” said Daniel Lunz, chief executive officer of Previse. “We look forward to the advancements to care we can make together for patients with GI diseases-our technologies, combined with Castle’s TissueCypher test and history of executional success.”
The transaction is expected to close in the coming weeks, subject to the customary closing conditions.
About Previse and Esopredict
Established in 2018, Previse is a gastrointestinal health company with a primary focus on chronic acid reflux related diseases, including esophageal cancer. Previse's mission is to save lives and improve patient health through prevention and early detection. Previse leverages groundbreaking biomarker technology developed by Stephen Meltzer, M.D., and his GI Early Detection Biomarker Lab at the Johns Hopkins University School of Medicine and exclusively licensed to Previse. This technology, backed by funding from the National Institutes of Health (NIH) and decades of research, forms the foundation of Previse's commitment to combating GI diseases, including cancer. At the forefront is Esopredict®, a highly sensitive epigenetic test designed to predict the risk of progression to high-grade dysplasia or esophageal adenocarcinoma in patients with precancerous Barrett's esophagus.
About Castle Biosciences
Castle Biosciences (Nasdaq: CSTL) is a leading diagnostics company improving health through innovative tests that guide patient care. The Company aims to transform disease management by keeping people first: patients, clinicians, employees and investors.
Castle’s current portfolio consists of tests for skin cancers, Barrett’s esophagus, mental health conditions and uveal melanoma. Additionally, the Company has active research and development programs for tests in other diseases with high clinical need, including its test in development to help guide systemic therapy selection for patients with moderate-to-severe atopic dermatitis seeking biologic treatment. To learn more, please visit www.CastleBiosciences.com and connect with us on LinkedIn, Facebook, X and Instagram.
DecisionDx-Melanoma, DecisionDx-CMSeq, DecisionDx-SCC, MyPath Melanoma, DiffDx-Melanoma, TissueCypher, IDgenetix, DecisionDx-UM, DecisionDx-PRAME and DecisionDx-UMSeq are trademarks of Castle Biosciences, Inc.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the “safe harbor” created by those sections. These forward-looking statements include, but are not limited to, statements concerning: the ability of the Previse acquisition to complement Castle’s current gastroenterology franchise; Castle’s growth initiatives; Castle’s ability to expand its offerings, address existing unmet needs and realize upstream opportunities; the closing of the acquisition of Previse on the agreed terms, or at all. The words “believe,” “can” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements that we make. These forward-looking statements involve risks and uncertainties that could cause our actual results to differ materially from those in the forward-looking statements, including, without limitation: subsequent study or trial results and findings may contradict earlier study or trial results and findings or may not support the results obtained in these studies, including with respect to the discussion of our tests in this press release; actual application of our tests may not provide the aforementioned benefits to patients; and the risks set forth under the heading “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2024, and in our other filings with the SEC. The forward-looking statements are applicable only as of the date on which they are made, and we do not assume any obligation to update any forward-looking statements, except as may be required by law.
Investor and Media Contact:
Camilla Zuckero
281-906-3868
[email protected]
